GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Securities & Investments

BioPharma Credit (LSE:BPCR) Securities & Investments : $0.0 Mil (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Securities & Investments?

BioPharma Credit Securities & Investments Historical Data

The historical data trend for BioPharma Credit's Securities & Investments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Securities & Investments Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Securities & Investments
Get a 7-Day Free Trial - - - - -

BioPharma Credit Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Dec23
Securities & Investments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Securities & Investments that banks have, including equity investments and bonds etc.

BioPharma Credit Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Securities & Investments
Comparable Companies
LSE:HRI LSE:BBGI LSE:AGT LSE:SYNC LSE:MUT LSE:FSV LSE:IEM LSE:TRY LSE:LWDB LSE:ASL BLK BX OSTO:INVE A TSX:BN KKR APO BK AMP XSWX:PGHN LSE:III
Traded in Other Exchanges
N/A
Address
65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ
Website
https://www.bpcruk.com
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit Headlines

No Headlines